A study comparing low-dose and standard-dose of tablet Ticagrelor three months after heart stent treatment for a heart attack.

Comparison of low dose versus standard dose Ticagrelor 3 months after Percutaneous coronary intervention for acute coronary syndrome. - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/101416

Enrollment

1530

Registered

2026-01-16

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I219- Acute myocardial infarction, unspecified

Interventions

Intervention1: Administration of standard(90 mg) vs low dose ticagrelor(60 mg) 3 months after PCI for ACS.: PATIENTS WHO UNDERWENT PCI FOR ACS WILL BE GIVEN DUAL ANTIPLATELETS TABLET ASPRIN 75MG ONCE

Eligibility

Inclusion criteria

Inclusion criteria: PATIENTS WITH ACS UNDERGOING PCI.

Exclusion criteria

Exclusion criteria: Contraindication to Ticagrelor, Indication for anticoagulation therapy, Any component of NACE in the 3 months preceeding randomization, LVEF less than 35, pregnancy or lactation, life expectancy less than a year, patients planned for staged PCI, Poor compliance

Design outcomes

Primary

Measure	Time frame
Difference in Net adverse Clinical events (NACE - Composite of death from any cause, myocardial infarction, stroke, and major bleeding) between the 2 groups at 1 year.Timepoint: At 1 year	—

Secondary

Measure	Time frame
Difference in Major Adverse Cardiac and Cerebrovascular Events (MACCE - a composite of death from any cause, myocardial infarction, or stroke) between both groups at year Difference in rates of major or clinically relevant non-major bleed between the 2 groups at 1 year Difference in rates of Definite, Probable or Possible stent thrombosis between the 2 groups at 1 year Difference in platelet reactivity suppression between the 2 groupsTimepoint: At 1 year	—

Measure

Time frame

Difference in Major Adverse Cardiac and Cerebrovascular Events (MACCE - a composite of death from any cause, myocardial infarction, or stroke) between both groups at year Difference in rates of major or clinically relevant non-major bleed between the 2 groups at 1 year Difference in rates of Definite, Probable or Possible stent thrombosis between the 2 groups at 1 year Difference in platelet reactivity suppression between the 2 groupsTimepoint: At 1 year

—

Countries

India

Contacts

Public ContactLovedeep singh

G B PANT HOSPITAL, DELHI

safal.rediffmail.com9718592497

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026